Roche reports strong 2024 results with 7% sales growth

30 January 2025

Swiss pharma giant Roche (ROG: SIX) today released full-year 2024 financials, showing that group sales grew 7% at constant exchange rates (3% in francs) to 60.5 billion francs ($66.9 billion).

In 2024, core earnings rose by 7% at CER, and would have risen by 12% excluding the impact of the resolution of a tax dispute dating back to 2023.

Operating profit rose by 14% to 20.8 billion francs, slightly below the consensus target of 20.9 billion francs, driven by higher sales, improved gross margin and effective cost management.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical